Shanghai Haoyuan Biotech Co.,Ltd. ("Shanghai Haoyuan") is a pioneer of the research and development of nucleic acid detection (NAT) technology, and also a leader of the blood screening by NAT technology in blood centers in China. Professor Huang Daopei , a senior molecular biologist, working in U.S. for many years, realised that the detection methods for hepatitis B virus (HBV) was undeveloped and lag behind in China where almost 10% populations were infected with HBV. Therefore, he raised funds about 100,000 dollars from patriots in America and came back to Shanghai and established Shanghai Haoyuan BioTechnology Company in 1997. Ever since then, it has opened a new chapter of NAT technology for infectious diseases in China.

After ten years of painstaking efforts, Shanghai Haoyuan formed a strategic alliance with Medigen Biotechnology Corp. Taiwan and Texas Biogene U.S.. With the talent production researchers and technical resources from these three sites, a series of newest generation of NAT products for blood screening have been developed in recent years. These products integrate the design idea for simultaneous detection of HIV, HCV and HBV in one sample with five different fluorescence PCR technique, leading the blood screening by NAT technology in worldwide.

Shanghai Haoyuan will spare no efforts in endeavoring to develop some simple performance and high quality NAT products with highest sensitivity and specificity. Our company will be dedicated to serve for medical and health organizations including blood centers, hospitals and blood product enterprises, and will make our great contribution to human health.